MedPage Today
Ten-year cancer rates rose from 1.84% at normal weight to 2.62% with class II obesity, with thyroid and endometrial cancers leading, researchers report.
Recap by typeshit. Full story at MedPage Today.
The review looks at concerns about misuse as demand for GLP-1 drugs grows, and points to how little evidence guides their use beyond approved conditions.
Researchers found self-reported GLP-1 use climbed from March 2024 to October 2025, mostly for weight loss, through channels insurance data may not capture.
The study is looking for women with hot flashes and night sweats and a BMI above 30. Mayo Clinic has the full eligibility rules and how to sign up.
A matched cohort study in Inflammatory Bowel Diseases found remission odds nearly six times higher on GLP-1 drugs, and weight loss alone didn't explain it.
Millions of Medicare beneficiaries may want in on the GLP-1 Bridge program, but eligibility rules mean not everyone will qualify.
9:33
A short clip from Dr. Jones DC on what he sees as the pros, cons and errors people make with the experimental drug retatrutide.
Loading…